MedTrace Logo

Effect of in Vitro Blocking the Common Beta Chain on Cell Viability in Asthma

NCT01759849 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 10

Last updated 2017-07-13

No results posted yet for this study

Summary

This study examines in vitro blockade of signaling through the β-chain, on viability, activation and differentiation of eosinophils and their progenitors collected in sputum, blood and bone marrow samples pre and post-allergen challenge from mild atopic asthmatic subjects.

Conditions

Interventions

OTHER

Allergen

Allergen extract is administered by inhalation.

Sponsors & Collaborators

  • CSL Limited

    collaborator INDUSTRY

  • Hamilton Health Sciences Corporation

    lead OTHER

Principal Investigators

  • Gail M Gauvreau, PhD · Hamilton Health Sciences Corporation

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-11-30
Primary Completion
2014-09-30
Completion
2014-09-30

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01759849 on ClinicalTrials.gov